Table 1

Clinical characteristics of the patients with systemic sclerosis and the control group.

Parametera

SSc patients

(n = 89)

Controls

(n = 48)


Female/male ratio

80/9

42/6c

Age, years

57.23 ± 12.31

53.71 ± 14.38c

Disease duration, yearsb

10.65 ± 9.00

Duration of Raynaud's phenomenon, years (data available for 54 patients only)

9.59 ± 8.45

dSSc/lSSc, number of patients

20/69

ANA-positive, n (%) patients

84 (94.38)

Anti-topo I-positive, n (%) patients

35 (39.33)

ACA-positive, n (%) patients

33 (37.08)

ILD by HRCT/radiograph, n (%) patients

55 (61.78)

Pulmonary hypertension, n (%) patients (data available for 81 patients only)

4 (4.94)

Digital ulcers, n (%) patients

38 (42.70)

Scleroderma renal crisis, n (%) patients

0

Arterial hypertension, n (%) patients

8 (9.00)

0

CCBs, n (%) patients

Pentoxyphylline, n (%) patients

ACEIs, n (%) patients

Sildenafil, n (%) patients

NSAIDs, n (%) patients

27 (30.34)

33 (37.08)

12 (13.48)

4 (4.49)

13 (14.61)

0

0

0

0

0


Values are given as mean ± SD unless stated otherwise. aData available for 89 patients unless stated otherwise; bcalculated from the time of the first non-Raynaud's symptom attributable to SSc; cstatistically non-significant (P >0.05). ACA, anticentromere antibodies; ACEIs, angiotensin-converting enzyme inhibitors; ANA, antinuclear antibodies; CCBs, calcium channel blockers; dSSc, diffuse systemic sclerosis; HRCT, high resolution computed tomography; lSSc, limited systemic sclerosis; ILD, scleroderma interstitial lung disease; NSAIDs, non-steroidal anti-inflammatory drugs. Detailed definitions of particular organ involvement are given in the methods section.

Kowal-Bielecka et al. Arthritis Research & Therapy 2013 15:R69   doi:10.1186/ar4246

Open Data